Meeting
2024 ASCO Annual Meeting
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.
Authors
Frederick M. Dirbas
Stanford Cancer Institute, Stanford, CA
Frederick M. Dirbas , Amichay Meirovitz , David Greenberg , Edith Dekel , Gavin S. Choy , Jedidiah Monson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05351502
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS2686)
DOI
10.1200/JCO.2024.42.16_suppl.TPS2686
Abstract #
TPS2686
Poster Bd #
156b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.
First Author: Ayumu Arakawa
Poster
2020 ASCO Virtual Scientific Program
SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.
First Author: Yongheng Liu
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2023 ASCO Annual Meeting
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
First Author: Benjamin L. Schlechter